Rules of the Game: How India’s Regulatory Architecture Is Shaping the Biocosmetics Revolution
India’s regulatory framework for cosmetics and biocosmetic products is evolving at a pace that reflects both the urgency of the opportunity and the complexity of governing a sector where the boundary between beautifying and healing is being actively redrawn by science.
Regulation is, in most public discourse, treated as a constraint — the bureaucratic apparatus that limits what companies can do, slows market entry, and imposes costs that would not otherwise exist. This framing is not entirely wrong, but it is profoundly incomplete, particularly in a sector like biocosmetics where the regulatory architecture does not merely constrain commercial behaviour but actively shapes the competitive landscape, defines the standards of consumer protection, and — critically — determines which companies can credibly claim the scientific legitimacy that increasingly drives consumer purchasing decisions. In India’s biocosmetics sector, the regulatory framework is as much a strategic variable as it is an operational constraint. Understanding it — its current structure, its recent evolution, its remaining gaps, and its relationship to international standards — is essential for any serious engagement with the sector’s future.
India’s cosmetics regulatory architecture sits at the intersection of multiple institutional authorities, legislative frameworks, and internationally derived standards. Navigating this architecture is not simple, and the difficulty of navigation is itself both a challenge and an opportunity: a challenge for smaller innovators with limited regulatory capacity, and an opportunity for those — typically science-led companies with strong documentation practices — who can demonstrate compliance convincingly and use that demonstrated compliance as a commercial differentiator.
CDSCO and the Cosmetics Rules 2020
The primary regulatory authority for cosmetics in India is the Central Drugs Standard Control Organization (CDSCO), operating under the Ministry of Health and Family Welfare. The CDSCO’s cosmetics mandate derives from the Drugs and Cosmetics Act, 1940 — a legislative instrument that, despite its age, has been updated periodically to address new scientific and commercial realities. The most significant recent update came through the Cosmetics Rules, 2020, which replaced several provisions of the earlier schedule-based system with a more comprehensive and internationally aligned framework.
The Cosmetics Rules, 2020 establish the standards that all cosmetics manufactured in or imported into India must meet, as prescribed under the Ninth Schedule. These standards cover safety assessment requirements, prohibited and restricted ingredient lists, good manufacturing practice (GMP) standards, labelling requirements — including mandatory ingredient disclosure in INCI nomenclature — and import licensing procedures. The updated rules also brought India’s cosmetics regulatory framework into closer alignment with the harmonised ASEAN Cosmetics Directive, facilitating mutual recognition arrangements that simplify the regulatory pathway for Indian cosmetics brands seeking to export to Southeast Asian markets.
For biocosmetics companies specifically, the Cosmetics Rules, 2020 provide a workable — if not always straightforward — regulatory pathway for products built on novel fermented, bioengineered, or bio-identical actives, provided those actives are not subject to specific ingredient restrictions and the products’ claims remain within the cosmetic rather than the drug classification. The mandatory INCI labelling requirement, while adding compliance cost, actually benefits biocosmetics brands by requiring ingredient transparency that differentiates scientifically grounded formulations from those built on vague ‘natural’ or ‘herbal’ claims.
The 2025 Borderline Guidelines
The most consequential recent development in India’s cosmetics regulatory landscape is the CDSCO’s 2025 guidelines on borderline products — a regulatory document that has significant implications for the entire biocosmetics sector and represents one of the most important shifts in Indian cosmetics governance in a generation. Borderline products are those that straddle the definitional boundary between a cosmetic — a product intended to clean, beautify, promote attractiveness, or alter appearance — and a drug — a product intended to diagnose, cure, treat, or prevent disease, or to affect the structure or function of the body.
The category of borderline products has always existed, but the proliferation of biocosmetic ingredients with documented physiological effects — EGF that stimulates cell regeneration, fermented peptides that measurably increase skin density, stem cell secretomes that activate fibroblast activity — has expanded the borderline zone dramatically. Products making claims such as ‘stimulates collagen synthesis,’ ‘repairs the skin barrier,’ ‘reduces inflammatory response,’ or ‘activates skin’s regenerative processes’ are, under the 2025 guidelines, potentially classifiable as drugs rather than cosmetics — a reclassification that triggers full drug licensing requirements, including clinical dossier submission, pharmacovigilance obligations, and manufacturing compliance with drug GMP standards rather than the less stringent cosmetic GMP requirements.
The practical implications of these guidelines are double-edged. For large, well-resourced biocosmetics companies that already generate clinical data to support their efficacy claims — and that have the regulatory infrastructure to manage drug licensing processes — the guidelines represent a competitive moat. Their products can make the mechanistic efficacy claims that resonate with scientifically literate consumers precisely because they have undergone the level of regulatory scrutiny that validates those claims. For smaller companies that have been making quasi-physiological efficacy claims without adequate clinical substantiation, the guidelines represent a genuine compliance challenge that will require either significant investment in clinical validation or a retreat to less ambitious product positioning.
“The CDSCO’s 2025 borderline guidelines do not just regulate claims — they redefine what it means to compete credibly in the biocosmetics market. Science is now the entry ticket, not the differentiator.”
The consumer protection rationale for the 2025 guidelines is sound and should not be obscured by the compliance burden they impose. In a market where biocosmetics products can plausibly claim to influence biological processes at the cellular level — and where consumers are increasingly likely to believe and act on such claims — the absence of a rigorous evidentiary standard for those claims would be a significant consumer protection failure. The guidelines are a necessary counterpart to the sector’s growing scientific ambition: if biocosmetics is going to claim the credibility of drug-grade science, it must accept the accountability of drug-grade regulation.
Gaps, Inconsistencies& Navigation Challenge
Acknowledging the regulatory framework’s strengths does not require ignoring its limitations. India’s cosmetics regulatory architecture, despite its recent evolution, contains gaps and inconsistencies that create genuine challenges for biocosmetics innovators, particularly those operating at the frontier of ingredient science where established regulatory categories provide imperfect guidance.
The classification of stem cell-derived ingredients is one of the most complex regulatory questions in the Indian biocosmetics space. Stempeutics Research’s Stempeucare™ range holds DCGI approval under Form 46, but the regulatory pathway for stem cell-derived cosmetic actives is not yet clearly codified in a way that would allow other companies to replicate or build on that pathway with confidence. The absence of a specific regulatory framework for biological actives derived from cell culture — distinct from both conventional cosmetics and pharmaceutical biologics — creates uncertainty that increases the time and cost of regulatory navigation for innovators in this space.
The regulation of microbiome-targeted products presents similar definitional challenges. Products containing live probiotic cultures occupy an uncertain regulatory space between food supplements, medical devices, and cosmetics. Postbiotic formulations — which contain fermentation metabolites rather than live organisms — are generally classifiable as cosmetics, but the evidentiary standards for their efficacy claims are not clearly defined. The 2025 borderline guidelines provide some directional guidance, but the specific application of those guidelines to the diversity of microbiome-targeted product formats requires further regulatory elaboration.
Small and medium-scale manufacturers — a numerous and important tier in India’s biocosmetics supply chain — face disproportionate regulatory navigation challenges relative to their larger competitors. The complexity of the Cosmetics Rules, 2020, the evolving borderline guidelines, and the diverse requirements of international export markets create a compliance burden that requires regulatory expertise that smaller companies often lack and cannot easily afford to acquire. The IKP Global Regulatory Forum and similar platforms provide some assistance, but a more structured government-supported regulatory guidance programme for SME biocosmetics manufacturers would materially strengthen this tier of the ecosystem.
Aligning with International Standards
India’s biocosmetics regulatory framework does not exist in isolation — it operates in a global context in which Indian-made products are increasingly seeking access to demanding international markets in Europe, North America, the Gulf, and East Asia. Each of these markets has its own regulatory framework for cosmetics and cosmeceuticals, and the degree of alignment between Indian regulations and those frameworks directly determines the ease and cost of market entry for Indian exporters.
The European Union’s Cosmetics Regulation (EC 1223/2009) is the most comprehensive and demanding cosmetics regulatory framework in the world, requiring extensive safety assessments, a designated Responsible Person in the EU, Product Information File (PIF) documentation, and a notification procedure through the Cosmetic Products Notification Portal (CPNP). For Indian biocosmetics companies seeking EU market access, alignment of their domestic regulatory documentation with EU requirements is a significant but achievable compliance investment — and one that pays dividends not only in EU market access but in the overall quality and credibility of the company’s regulatory posture.
The ASEAN harmonised framework — with which India’s Cosmetics Rules, 2020 are increasingly aligned — provides a more immediately accessible export pathway, particularly for the rapidly growing beauty markets of Southeast Asia. The Gulf Cooperation Council markets, where demand for premium science-led skincare is growing rapidly among a young, affluent, and digitally engaged consumer population, apply regulatory frameworks that are generally more permissive than the EU but still require careful navigation. India’s biocosmetics companies that invest in international regulatory capability early — building the documentation systems, the safety assessment processes, and the regulatory expertise required for multi-market compliance — will gain a structural advantage in the race to establish global brand presence before the sector’s competitive landscape fully consolidates.
The regulatory story of India’s biocosmetics sector is, ultimately, a story of a framework in constructive transition — moving from a system designed primarily to prevent harm toward one increasingly capable of both protecting consumers and enabling the kind of ambitious, evidence-based innovation that the sector’s scientific foundations now make possible. The transition is incomplete, and its remaining gaps are real. But the direction of travel is clear, and it points toward a regulatory environment that will, in time, be as much an asset to India’s global biocosmetics ambitions as the scientific talent and institutional infrastructure that support them.
–Deepika Mishra
